Login to Your Account



DON'T FORGET PANCREATIC

Newlink's phase III patient picks, antibody levels IMPRESS

By Randy Osborne
Staff Writer

Monday, June 2, 2014
in_the_clinic.jpg

CHICAGO – With immuno-oncology all the rage, especially against melanoma, at the 50th annual meeting of American Society of Clinical Oncology, the pairing of potential new compounds with ipilimumab (Yervoy, Bristol-Myers Squibb Co.) proved a popular ploy.

Checkpoint inhibitors are in the game.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription